Welcome to our dedicated page for Cogent Biosciences news (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.
Cogent Biosciences, Inc. (Nasdaq: COGT) generates frequent news flow as a biotechnology company developing precision therapies for genetically defined diseases. Its updates often center on the clinical and regulatory progress of bezuclastinib, a selective tyrosine kinase inhibitor designed to inhibit KIT D816V and other KIT exon 17 mutations associated with systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST).
News for COGT commonly includes clinical trial milestones from the pivotal SUMMIT, APEX and PEAK studies. SUMMIT evaluates bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM), APEX in Advanced Systemic Mastocytosis (AdvSM), and PEAK in imatinib-resistant or intolerant GIST in combination with sunitinib. Press releases have highlighted positive top-line results, detailed efficacy and safety data, and plans for New Drug Application (NDA) submissions to the U.S. Food and Drug Administration.
Investors and followers of COGT can also expect regulatory and designation announcements, such as Breakthrough Therapy Designation for bezuclastinib in specific NonAdvSM populations, as well as updates on Expanded Access Programs for eligible GIST and SM patients. Financial and corporate news appears regularly, including equity and convertible note offerings, cash runway commentary, and participation in major healthcare investor conferences like the J.P. Morgan Healthcare Conference and the Jefferies Global Healthcare Conference.
In addition, Cogent issues news on its early-stage pipeline, including a selective and potent FGFR2/3 inhibitor in Phase 1/2 and discovery programs targeting ErbB2, PI3Kα, KRAS and JAK2. For readers tracking COGT, this news page provides an organized view of trial readouts, regulatory plans, financing events and scientific presentations that shape the company’s development trajectory. Bookmark this feed to monitor Cogent’s ongoing disclosures about its precision oncology and hematology programs.
Cogent Biosciences, Inc. (Nasdaq: COGT) reported on track clinical trial enrollment for three studies with topline results expected in 2025. The company ended the first quarter of 2024 with $435.7 million in cash, sufficient to fund operations until 2027. Recent business highlights include positive clinical data from SUMMIT trial and oversubscribed private placement.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.